González, C., Lasa, M., Agullo, C., Buenache, N., Notarfranchi, L., Zherniakova, A., Calasanz, M., Castro, S., Pérez, J., Gonzalez-Calle, V., Romero, M. T. C., Martín-Muñoz, A., Garcia, S. B., Oriol, A., Ocio, E., Balarí, A. S., González-Montes, Y., Ramirez, A., Dachs, L. R., Lopez-Guia, A., Bargay, J., Lakhwani, S., Montero, L. F. C., Creixenti, J. B. B., Palacios, J. L., San-Miguel, J., Mateos, M., Martínez-López, J., Puig, N., Paiva, B. (2025). Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial. Blood. https://doi.org/10.1182/blood-2025-919